imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agentes antineoplásicos - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - carcinoma, pulmón no microcítico - agentes antineoplásicos - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
imfinzi® 50 mg/ml concentrado para solución para perfusión
durvalumab - concentrado para solución para perfusión - 50 mg/ml
dupixent®
sanofi - aventis groupe francia - dupilumab 300 mg - solucion inyectable - cada jeringuilla precargada contiene (a): dupilumab 300 mg
dupixent® 200 mg / 1.14 ml
sanofi - aventis groupe francia - dupilumab 200 mg - soluciÓn inyectable - cada jeringuilla precargada contiene (a): dupilumab 200 mg
apoquel
zoetis belgium sa - maleato de oclacitinib - agentes para la dermatitis, excluidos los corticosteroides - perros - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.
cibinqo comprimidos recubiertos 100 mg (abrocitinib)
pfizer chile s.a. - abrocitinib - sin formulas
cibinqo comprimidos recubiertos 200 mg (abrocitinib)
pfizer chile s.a. - abrocitinib - sin formulas
cibinqo comprimidos recubiertos 50 mg (abrocitinib)
pfizer chile s.a. - abrocitinib - sin formulas
agacel®
tuteur s.a.c.i.f.i.a. - imatinib (eq. a 478 mg de mesilato de imatinib) - comprimido recubierto - 400 mg